Subsequent Events - Additional Information (Detail) - AstraZeneca [Member] |
3 Months Ended | |
|---|---|---|
|
May 02, 2017
USD ($)
Program
|
Mar. 31, 2017
USD ($)
|
|
| Subsequent Event [Line Items] | ||
| Contractual agreement, potential payments | $ 57,500,000 | |
| License and Collaboration Agreement [Member] | ||
| Subsequent Event [Line Items] | ||
| Agreement termination description | The Collaboration Agreement may be terminated by AstraZeneca in its entirety for convenience beginning 12 months after its effective date upon 90 days’ notice or, if Pieris has obtained marketing approval for the marketing and sale of a product, 180 days’ notice. Each program may be terminated at AstraZeneca’s option; if any program is terminated by AstraZeneca, Pieris will have full rights to such program. The Collaboration Agreement may also be terminated by AstraZeneca or Pieris for material breach upon 180 days’ notice of a material breach (or 30 days with respect to payment breach), provided that the applicable party has not cured such breach by the permitted cure period (including an additional 180 days if the breach is not susceptible to cure during the initial 180-day period) and dispute resolution procedures specified in the applicable Agreement have been followed. The Collaboration Agreement may also be terminated due to the other party’s insolvency and may in certain instances be terminated on a product-by-product and/or country-by-country basis. Each party may also terminate the agreement if the other party challenges the validity of patents related to certain intellectual property licensed under the Agreements, subject to certain exceptions for infringement suits, acquisitions and newly-acquired licenses. The License Agreement will terminate upon termination of the Collaboration Agreement, on a product-by-product and/or country-by-country basis. | |
| License and Collaboration Agreement [Member] | Subsequent Event [Member] | ||
| Subsequent Event [Line Items] | ||
| Collaboration agreement, license upfront payment | $ 57,500,000 | |
| Number of therapeutic programs | Program | 5 | |
| Agreement termination notice period | 90 days | |
| Agreement termination notice period upon material breach by the Company | 180 days | |
| Agreement termination notice period upon breach of payment obligations by the Company | 30 days | |
| Maximum [Member] | License and Collaboration Agreement [Member] | Subsequent Event [Member] | ||
| Subsequent Event [Line Items] | ||
| Contractual agreement, potential payments | $ 2,100,000,000 | |
| Upfront Payment Arrangement [Member] | License and Collaboration Agreement [Member] | Subsequent Event [Member] | ||
| Subsequent Event [Line Items] | ||
| Collaboration agreement, license upfront payment | 45,000,000 | |
| Near Term Milestone Payments [Member] | License and Collaboration Agreement [Member] | Subsequent Event [Member] | ||
| Subsequent Event [Line Items] | ||
| Collaboration agreement, license upfront payment | $ 12,500,000 |